SVA SINOVAC BIOTECH LTD
Price Chart
Executive Summary
Sinovac Biotech received a Nasdaq delist determination letter on May 22, 2026 for failing to timely file its 2025 Annual Report (Form 20-F), just days after being placed on a mandatory one-year panel monitor for previous late filings. The company has requested a hearing, which automatically stays suspension for 22 days, but remains at high risk of eventual delisting if the 2025 Annual Report is not filed.
Actionable Insight
SVA faces imminent delisting risk. The 22-calendar-day stay from May 22 gives until approximately June 13, 2026 for a hearing decision or further stay. Traders should monitor for filing of the 2025 20-F or a Nasdaq hearing update. If no filing materializes before the stay expires, suspension and delisting are likely — expect elevated volatility and potential decline.
Key Facts
- Received Nasdaq Staff Determination dated May 22, 2026 for failure to timely file 2025 Annual Report (Form 20-F) by the required deadline.
- Company had just regained compliance on May 8, 2026 under a Nasdaq Panel decision dated January 21, 2026, and was placed on a mandatory one-year Panel Monitor.
- Hearing has been requested on May 29, 2026, which automatically stays suspension for 22 calendar days; a further stay has been requested pending the hearing process.
- If the hearing does not result in continued listing or the company fails to file the 2025 Annual Report during the stay, securities are subject to suspension and delisting.
Financial Impact
Potential delisting of SVA if the 2025 Annual Report is not filed and a hearing extension is not granted; no specific financial figures disclosed.
Risk Factors
- Delisting from Nasdaq if the 2025 Annual Report is not filed and the hearing does not result in a further extension.
- Repeated pattern of late filings suggests ongoing financial reporting or operational issues.
- Potential loss of investor confidence and liquidity if shares are suspended or delisted.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062907 |
| Document: ea0292646-6k_sinovac.htm | 0001213900-26-062907 |
| Document: 0001213900-26-062907-index-headers.html | 0001213900-26-062907 |
| Document: 0001213900-26-062907-index.html | 0001213900-26-062907 |
| Document: 0001213900-26-062907.txt | 0001213900-26-062907 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
20-F
| $6.47 awaiting T+5 | awaiting T+5 | — | $6.47 (+0.00%) |
|
May 29, 2026
14d ago
|
6-K
| $6.47 $6.47 | · 0.00% | ▼ −2.75% | $6.47 (+0.00%) |
|
May 21, 2026
22d ago
|
6-K
| $6.47 $6.47 | · 0.00% | ▼ −1.85% | $6.47 (−0.00%) |
|
May 8, 2026
5w ago
|
6-K
| $6.47 $6.47 | · 0.00% | ▼ −0.09% | $6.47 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access